AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15478912 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab/MMF/Steroids (Tacrolimus started when creatinine dropped below 350 micromol/l)
Number of subjects: 51
Study 15478912 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/MMF/Steroids
Number of subjects: 51
Study 15478912 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed introduction of Tacrolimus for machine perfused grafts
Number of subjects: 51
Study 11675838 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 1,000 units/kg
Number of subjects: 38
Study 11675838 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% 0.2 mL/kg (Control)
Number of subjects: 38
Study 9389779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gram gel containing 1 mg oestradiol for 3 months plus 20 mg oral MPA during the last 14 days
Number of subjects: 0
Study 9389779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g gel containing 2 mg oestradiol for 21 days plus 10 mg oral MPA during the last 14 days
Number of subjects: 0
Study 9389779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate tablets for 3 weeks plus 10 mg oral MPA during the last 10 days
Number of subjects: 0
Study 7701040 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg sublingual, max 16 mg), average dose 11.2 mg
Number of subjects: 51
Study 7701040 — intervention group
Group type: COMPARATOR
Intervention: Methadone (50 mg oral, max 90 mg), average dose 66.6 mg
Number of subjects: 51
Study 7701040 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine and Methadone
Number of subjects: 51
Study 3115632 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (500 mg at -60 min and at -30 min)
Number of subjects: 8
Study 3115632 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (500 mg) prior to GRF 1-44 (1 micrograms/kg i.v. at 0 min)
Number of subjects: 8
Study 3115632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3115632 — intervention group
Group type: COMPARATOR
Intervention: In-vitro basal GH release and GH responses to 10(-8)M GRF by rat anterior pituitary cells
Number of subjects: 8
Study 28224818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose docosahexaenoic acid (DHA) (260 mg or 520 mg/day)
Number of subjects: 28
Study 27593174 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly insulin degludec (IDeg) injected at twice the once-daily dose before lunch on Monday, Wednesday, and Friday
Number of subjects: 22
Study 24850107 — intervention group
Group type: COMPARATOR
Intervention: ITM 0.2 mg
Number of subjects: 90
Study 24850107 — intervention group
Group type: EXPERIMENTAL
Intervention: ITM 0.5 mg
Number of subjects: 90
Study 24850107 — intervention group
Group type: EXPERIMENTAL
Intervention: ITM 1 mg
Number of subjects: 90
Study 23539912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 120
Study 23539912 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 120
Study 23539912 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 120
Study 23539912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 120
Study 21226953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol and Probucol combination therapy
Number of subjects: 118
Study 21226953 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol monotherapy
Number of subjects: 118
Study 18316488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure with the STARFlex implant
Number of subjects: 147
Study 18316488 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 147
Study 16500237 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (Femara)
Number of subjects: 0
Study 16500237 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 14526151 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 17
Study 14526151 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 17
Study 10776008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 43
Study 10776008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8816539 — intervention group
Group type: COMPARATOR
Intervention: Metal stents (52 patients)
Number of subjects: 101
Study 8816539 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stents (49 patients)
Number of subjects: 101
Study 1483490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracolonic human calcitonin (hCT)
Number of subjects: 0
Study 1483490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous human calcitonin (hCT)
Number of subjects: 0
Study 3893112 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 2 mg/kg per day intravenously (n = 39)
Number of subjects: 77
Study 3893112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (12 to 15 mg/kg per day orally or 3 to 5 mg/kg per day intravenously) (n = 38)
Number of subjects: 77
Study 3893112 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 77
Study 3893112 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 77
Study 31382524 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 20
Study 31382524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study 29746682 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning course (non-compulsory, 6 weeks duration)
Number of subjects: 356
Study 26119561 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise voltage ramping (n=213)
Number of subjects: 418
Study 26119561 — intervention group
Group type: COMPARATOR
Intervention: Fixed maximal voltage (n=205)
Number of subjects: 418
Study 25102109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex real-time PCR assay
Number of subjects: 0
Study 22747752 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formulation (Synbiotic 2000®) containing 4 strains of probiotic bacteria (10^10 each) plus 4 nondigestible, fermentable dietary fibers (2.5 g each) daily for 4 weeks
Number of subjects: 0
Study 22747752 — intervention group
Group type: COMPARATOR
Intervention: Fiber-only placebo formulation
Number of subjects: 0
Study 22747752 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formulation (Synbiotic 2000®)
Number of subjects: 0
Study 20430604 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/500 microg bd
Number of subjects: 82
Study 20430604 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 microg bd
Number of subjects: 82
Study 17591479 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited fluoroscopy
Number of subjects: 199
Study 17591479 — intervention group
Group type: COMPARATOR
Intervention: Continuous fluoroscopy
Number of subjects: 199
Study 16075172 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound device
Number of subjects: 22
Study 16075172 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound device
Number of subjects: 22
Study 12173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microgram kg‐1 added to caudal bupivacaine
Number of subjects: 80
Study 12173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1 added to caudal bupivacaine
Number of subjects: 80
Study 12173195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1 i.v. and caudal bupivacaine
Number of subjects: 80
Study 12173195 — intervention group
Group type: COMPARATOR
Intervention: Caudal block with bupivacaine, no clonidine (control)
Number of subjects: 80
Study 10390291 — intervention group
Group type: EXPERIMENTAL
Intervention: Low repetition‐heavy load resistance training (1 set of 6 to 8 repetitions, n = 15)
Number of subjects: 43
Study 10390291 — intervention group
Group type: EXPERIMENTAL
Intervention: High repetition‐moderate load resistance training (1 set of 13 to 15 repetitions, n = 16)
Number of subjects: 43
Study 10390291 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 43
Study 8562299 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate 1200 mg every 12 h with vigabatrin 1000 mg every 12 h
Number of subjects: 36
Study 8562299 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 1000 mg every 12 h with felbamate 1200 mg every 12 h
Number of subjects: 36
Study 8562299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2177368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 18
Study 466335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous on-demand fentanyl infusion
Number of subjects: 0
Study 466335 — intervention group
Group type: COMPARATOR
Intervention: Epidural injections of bupivacaine
Number of subjects: 0
Study 31039663 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (WD)
Number of subjects: 45
Study 31039663 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (including WD, walnut FA-matched diet, oleic acid-replaced-ALA diet)
Number of subjects: 45
Study 31039663 — intervention group
Group type: COMPARATOR
Intervention: Walnut FA-matched diet
Number of subjects: 45
Study 28468648 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus Expedited Partner Therapy (EPT) with cefixime 400 mg/azithromycin 1 g for up to five recent partners; n=89.
Number of subjects: 173
Study 28468648 — intervention group
Group type: COMPARATOR
Intervention: Standard partner notification counseling; n=84.
Number of subjects: 173
Study 26052700 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 55
Study 26052700 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated patients)
Number of subjects: 55
Study 22664861 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid enteral feeding advancement (30 mL/kg/d)
Number of subjects: 92
Study 22664861 — intervention group
Group type: COMPARATOR
Intervention: Slow enteral feeding advancement (20 mL/kg/d)
Number of subjects: 92
Study 21654257 — intervention group
Group type: EXPERIMENTAL
Intervention: Any alcohol intake
Number of subjects: 2044
Study 21654257 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (≤14 g/day)
Number of subjects: 2044
Study 21654257 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol intake (>14 g/day)
Number of subjects: 2044
Study 21654257 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate beer intake
Number of subjects: 2044
Study 21654257 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate wine intake
Number of subjects: 2044
Study 19344946 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite Multibond
Number of subjects: 39
Study 19344946 — intervention group
Group type: COMPARATOR
Intervention: Syntac/Variolink Ultra
Number of subjects: 39
Study 19344946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both luting systems
Number of subjects: 39
Study 16762751 — intervention group
Group type: EXPERIMENTAL
Intervention: Color tissue Doppler (TD)
Number of subjects: 31
Study 16762751 — intervention group
Group type: COMPARATOR
Intervention: Spectral tissue Doppler (TD)
Number of subjects: 31
Study 15190794 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse flaring technique
Number of subjects: 48
Study 15190794 — intervention group
Group type: COMPARATOR
Intervention: Step back technique
Number of subjects: 48
Study 11791759 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PEX)
Number of subjects: 28
Study 11791759 — intervention group
Group type: COMPARATOR
Intervention: Drugs only (Control)
Number of subjects: 28
Study 9781781 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 7730872 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, BMI, and high alcohol consumption
Number of subjects: 3400
Study 7730872 — intervention group
Group type: COMPARATOR
Intervention: Other factors (sex, diabetes, triglycerides, HDL cholesterol, height)
Number of subjects: 3400
Study 7730872 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 3400
Study 7730872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 3400
Study 2648792 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid (ASA) once daily
Number of subjects: 100
Study 2648792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16322122 — intervention group
Group type: EXPERIMENTAL
Intervention: TEW+CT method
Number of subjects: 0
Study 16322122 — intervention group
Group type: EXPERIMENTAL
Intervention: TEW+Chang method
Number of subjects: 0
Study 16322122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chang method
Number of subjects: 0
Study 16322122 — intervention group
Group type: COMPARATOR
Intervention: xenon CT/CBF method
Number of subjects: 0
Study 30880405 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (three types, unspecified)
Number of subjects: 1008
Study 30880405 — intervention group
Group type: EXPERIMENTAL
Intervention: DASS42 anxiety and stress subscales
Number of subjects: 1008
Study 30880405 — intervention group
Group type: EXPERIMENTAL
Intervention: HRSD17 anxiety/somatisation factor
Number of subjects: 1008
Study 30880405 — intervention group
Group type: EXPERIMENTAL
Intervention: Common definitions of anxious depression
Number of subjects: 1008
Study 28467729 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4599
Study 28467729 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4599
Study 28467729 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane and Tamoxifen
Number of subjects: 4599
Study 25554563 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-02545920
Number of subjects: 392
Study 25554563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 25554563 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter interviews (<15 min)
Number of subjects: 392
Study 24254033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 6
Study 24254033 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 6
Study 21530211 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 2.4 g
Number of subjects: 56
Study 21530211 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 56
Study 19770798 — intervention group
Group type: EXPERIMENTAL
Intervention: PulseCO measurement during optimization of biventricular pacing
Number of subjects: 7
Study 19770798 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure measurement
Number of subjects: 7
Study 16798483 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Lichtenstein's repair
Number of subjects: 37
Study 16798483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal hernioplasty
Number of subjects: 37
Study 16798483 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Lichtenstein and laparoscopic hernioplasty)
Number of subjects: 37
Study 15259326 — intervention group
Group type: EXPERIMENTAL
Intervention: Name cues
Number of subjects: 2
Study 15259326 — intervention group
Group type: COMPARATOR
Intervention: Face cues
Number of subjects: 2
Study 11130217 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG 100 mg with steady‐state BUP 150 mg twice/day
Number of subjects: 12
Study 11130217 — intervention group
Group type: COMPARATOR
Intervention: LTG 100 mg
Number of subjects: 12
Study 9316823 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 2302 (0.06-2.00 mg/kg infused over 2 hr)
Number of subjects: 0
Study 9316823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8287864 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol in the cardioplegic solution
Number of subjects: 0
Study 8287864 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine pre-treatment and addition to the cardioplegic solution
Number of subjects: 0
Study 3817280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tioconazole cream 1%
Number of subjects: 341
Study 3817280 — intervention group
Group type: COMPARATOR
Intervention: Comparative imidazole (econazole or miconazole)
Number of subjects: 341
Study 3817280 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 341
Study 31784988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) treatment
Number of subjects: 33
Study 31784988 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 28723587 — intervention group
Group type: EXPERIMENTAL
Intervention: TeenBP clinical decision support tool (CDS)
Number of subjects: 1214
Study 28723587 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1214
Study 28744742 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD-11091
Number of subjects: 126
Study 28744742 — intervention group
Group type: COMPARATOR
Intervention: non-treatment
Number of subjects: 126
Study 25465324 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS plus drug coated balloon (DCB)
Number of subjects: 20
Study 25465324 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS) alone
Number of subjects: 20
Study 25465324 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC levels
Number of subjects: 20
Study 23127306 — intervention group
Group type: EXPERIMENTAL
Intervention: oral hygiene instruction and chlorhexidine mouthrinse
Number of subjects: 102
Study 23127306 — intervention group
Group type: EXPERIMENTAL
Intervention: oral hygiene instruction, chlorhexidine mouthrinse, and assisted brushing
Number of subjects: 102
Study 23127306 — intervention group
Group type: COMPARATOR
Intervention: oral hygiene instruction alone
Number of subjects: 102
Study 21047828 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP200 (nevirapine initiation by dose escalation)
Number of subjects: 18
Study 21047828 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP400 (nevirapine initiation at 200 mg twice daily)
Number of subjects: 18
Study 21047828 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP200
Number of subjects: 18
Study 21047828 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP400
Number of subjects: 18
Study 18799723 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHVP+I (rituximab combined with CHVP and interferon)
Number of subjects: 0
Study 18799723 — intervention group
Group type: COMPARATOR
Intervention: CHVP+I (chemotherapy plus interferon)
Number of subjects: 0
Study 16683297 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniocentesis group
Number of subjects: 254
Study 16683297 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (605 women attending routine ultrasound)
Number of subjects: 254
Study 12885713 — intervention group
Group type: EXPERIMENTAL
Intervention: RTUF
Number of subjects: 70
Study 12885713 — intervention group
Group type: COMPARATOR
Intervention: F100
Number of subjects: 70
Study 10533170 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education methods in Trial I
Number of subjects: 3
Study 10533170 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education methods in Trial II
Number of subjects: 3
Study 10533170 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education methods in Trial III
Number of subjects: 3
Study 10533170 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient SR rate representing a 50% or more decrease in smoking
Number of subjects: 3
Study 8911858 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 60
Study 8911858 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study 1750722 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 120 mg twice a day
Number of subjects: 49
Study 1750722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7127660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral adjuvant razoxane (ICRF-159)
Number of subjects: 176
Study 7127660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study 30322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage adenoidectomy
Number of subjects: 65
Study 30322828 — intervention group
Group type: COMPARATOR
Intervention: Microdebrider adenoidectomy
Number of subjects: 65
Study 30773689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol lock therapy (ELT)
Number of subjects: 0
Study 30773689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28053054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 115
Study 28053054 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 115
Study 28053054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin and Infliximab
Number of subjects: 115
Study 27151007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with methotrexate
Number of subjects: 58
Study 27151007 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate combined with whole brain radiotherapy
Number of subjects: 58
Study 24183730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training/behavioral therapy
Number of subjects: 40
Study 24183730 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 22520520 — intervention group
Group type: EXPERIMENTAL
Intervention: Promus Element
Number of subjects: 1788
Study 22520520 — intervention group
Group type: COMPARATOR
Intervention: Resolute Integrity
Number of subjects: 1788
Study 20589696 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 108
Study 20589696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 20589696 — intervention group
Group type: EXPERIMENTAL
Intervention: Not achieving MDA
Number of subjects: 108
Study 17549054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) infusions
Number of subjects: 43
Study 17549054 — intervention group
Group type: COMPARATOR
Intervention: No fresh frozen plasma (FFP) infusions
Number of subjects: 43
Study 17549054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results from FFP group
Number of subjects: 43